-
IPR-803 and uPAR–uPA Inhibition in Metastasis
2026-10-10
The reference study evaluated compound 4, commonly associated with IPR-803, as a small-molecule blocker of the urokinase receptor–urokinase interaction. By combining direct-binding assays, breast cancer cell models, pharmacokinetics, and an orthotopic metastasis model, the authors established a preclinical rationale for targeting uPAR while also defining important limits on interpretation.
-
Cyclosporin A: Mechanism and Evidence
2026-10-10
Cyclosporin A, also called cyclosporine, is a cyclophilin-binding immunosuppressant whose best-established molecular action is inhibition of the calcineurin–NFAT pathway. Research models also use it to interrogate mitochondrial permeability transition and mitophagy, but these applications require careful interpretation because the compound is not a pathway-specific probe.
-
CP-673451: Evidence for Selective PDGFR Inhibition
2026-10-09
CP-673451 is described as a selective PDGFRα/β inhibitor for cancer research, with supplier-reported biochemical, cellular, and animal-model activity. Peer-reviewed evidence supports a broader research hypothesis: ATRX-deficient high-grade glioma cells may be more vulnerable to RTK and PDGFR inhibition, although the supplied study does not independently establish CP-673451 as the responsible compound or demonstrate clinical benefit.
-
IDH2, α-KG, and HIF-1α in Colorectal Cancer
2026-10-09
The reference study links elevated IDH2 activity with reductive citrate-cycle metabolism, α-ketoglutarate depletion, HIF-1A stabilization, and colorectal cancer progression. Its central contribution is a mechanistic model in which IDH2 supports tumor bioenergetics and glycolytic adaptation, while IDH2 inhibition disrupts this metabolic state in cell and animal models.
-
JC-1 in Mitochondrial Membrane Potential Research
2026-10-08
This overview explains how JC-1 can support interpretation of mitochondrial membrane potential, apoptosis detection, and cellular bioenergetics studies. It also places the dye in context with a 2026 palbociclib nanocrystal study, distinguishing reported findings from conceptual applications and highlighting important assay limitations.
-
Cabamiquine Pharmacodynamics: Fast Arrest, Slow Clearance
2026-10-08
Demarta-Gatsi and colleagues show that cabamiquine rapidly blocks Plasmodium falciparum protein translation, yet parasite death and blood-stage clearance occur later. By combining orthogonal in vitro assays, the study separates an early molecular pharmacodynamic effect from delayed loss of parasite viability, offering a clearer framework for interpreting clinical clearance kinetics.
-
HNRNPU Lactylation Rewires Cervical Cancer Metabolism
2026-10-07
A 2026 Advanced Science study identifies HNRNPU lysine 181 lactylation as a lactate-responsive mechanism that stabilizes HNRNPU, preserves PHGDH mRNA, and activates serine biosynthesis in cervical cancer. The work connects a metabolic signal to post-transcriptional RNA regulation and provides a rationale for studying this axis, while its pharmacological findings require validation beyond the reported models.
-
MRTFA-KCNMB1 Axis in Cancer Cell Stiffness
2026-10-07
Gajda et al. identify potassium efflux and the BK-channel auxiliary subunit KCNMB1 as regulators of cancer-cell stiffness downstream of MRTFA. The study connects softer cancer cells with immune evasion and metastatic colonization, while genetic or pharmacological BK-channel activation increased stiffness and improved immune-mediated clearance in preclinical models.
-
Berberine, SIRT6-AMPK, and Atrial Fibrillation
2026-10-06
A 2026 study links berberine’s protection against angiotensin II-induced atrial remodeling to activation of the SIRT6-AMPK axis and suppression of NLRP3 inflammasome signaling. Its integrated human-sample, bioinformatics, and murine-model evidence supports a mechanistic hypothesis for atrial fibrillation prevention, while remaining preclinical and model-dependent.
-
Cepharanthine in Endometriosis: Evidence and Limits
2026-10-06
A 2026 study evaluates Cepharanthine across stromal-cell models, patient-derived endometrial organoids, and a murine peritoneal endometriosis model. Its findings connect reduced lesion growth with G0/G1 arrest, DNA-damage signaling, impaired repair-associated markers, and apoptosis, while important questions about selectivity, safety, and clinical translation remain unresolved.
-
Concanamycin A: From V-ATPase to Autophagy
2026-10-05
Concanamycin A is a V-type H+-ATPase inhibitor that reveals how organelle acidification shapes autophagy, trafficking, and cancer biology research. This article connects its pharmacological mechanism with a landmark Arabidopsis study while clarifying what the evidence can—and cannot—show.
-
2-D08 and SUMOylation: Evidence and Limits
2026-10-04
2-D08, also known as 2’,3’,4’-trihydroxyflavone, is described as a mechanistically distinct SUMOylation inhibitor, but current evidence supports its use as a research tool rather than a validated therapy. A 2026 bronchopulmonary dysplasia study strengthens interest in SUMO-regulated mitochondrial quality control while providing no direct evidence for 2-D08 in that disease model.
-
(R)-MG132: Evidence and Research Context
2026-10-03
(R)-MG132 is described by APExBIO as a markedly less active stereoisomer of MG-132 and a potential negative control for proteasome-related research. This overview separates supplier-reported properties from peer-reviewed evidence, explains its conceptual role in ubiquitin-proteasome system research, and examines why findings from a recent HNRNPU lactylation study in cervical cancer should not be treated as direct evidence for (R)-MG132 activity or applicability.
-
5-AZA-2'-Deoxycytidine Toxicity in Mice
2026-10-02
Momparler and Frith established a clinically motivated mouse toxicology framework for continuous intravenous 5-AZA-2'-deoxycytidine, combining lethality estimation with serial hematologic and histopathologic assessment. The findings define dose-limiting marrow and gastrointestinal injury, while also showing substantial recovery of several lesions, providing an important safety foundation for later Decitabine research.
-
Exo1 and the Next Era of Tumor Vesicle Research
2026-10-01
Exo1, also known as methyl 2-(4-fluorobenzamido)benzoate, offers a mechanistically distinct way to interrogate Golgi–ER traffic, ARF1 behavior, and exocytic output. This thought-leadership guide connects that tool to tumor extracellular vesicle research while separating experimentally supported conclusions from translational hypotheses.